Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing

The Food and Drug Administration gave Intellia Therapeutics (NTLA) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed its premarket gains.